Business Context and Reporting Period
This Form 8-K filing by Conduit Pharmaceuticals Inc. (CDT) covers events occurring on December 17, 2024, and December 18, 2024. The Company is an emerging growth company incorporated in Delaware with principal executive offices in Naples, FL. The filing addresses critical listing status issues with The Nasdaq Stock Market and the results of the Company's 2024 Annual Meeting of Stockholders.
Key Financial Metrics
The filing does not provide specific financial statements, revenue, profit, cash flow, or debt figures. The primary financial metric disclosed is the trading price of the Company's securities, which closed at $0.10 or less for ten consecutive trading days as of December 17, 2024, triggering the "Low Priced Stocks Rule."
Material Changes and Corporate Actions
- Nasdaq Delisting Notice: Nasdaq determined that CDT's securities had a closing bid price of $0.10 or less for ten consecutive trading days. Unless a hearing is requested, delisting was scheduled for December 27, 2024. The Company intends to request a hearing to stay the delisting action.
- Reverse Stock Split Approval: At the Annual Meeting on December 18, 2024, stockholders approved an amendment to the Certificate of Incorporation to effect a reverse stock split with a ratio between 1-for-10 and 1-for-100. The exact ratio is at the Board's discretion and is intended to regain compliance with Nasdaq listing rules.
- Audit Committee Compliance: The appointment of Simon Fry as a director and member of the Audit Committee became effective on December 18, 2024. Consequently, Nasdaq notified the Company on December 20, 2024, that it had regained compliance with Listing Rule 5605(c)(2) regarding audit committee requirements.
Guidance, Outlook, and Risks
Management plans to present a compliance plan at the upcoming Nasdaq Hearings Panel hearing and request an extension of time to regain compliance with the Low Priced Stocks Rule. The Company explicitly states there are no assurances that a hearing will occur or that a favorable decision will be obtained. The common stock and warrants will continue to trade on Nasdaq pending the conclusion of the hearing process, subject to other ongoing listing deficiencies.
Investor Verification Checklist
- Verify the exact reverse stock split ratio once determined by the Board of Directors.
- Monitor the status and outcome of the hearing before the Nasdaq Hearings Panel regarding the Low Priced Stocks Rule.
- Confirm the continued listing status of CDT and CDTTW on The Nasdaq Stock Market following the hearing decision.
- Review the Company's plan to evidence compliance with Nasdaq rules as presented at the hearing.